Key result
ACC/AHA risk tool best predicts fatal CVD in MASLD with up to 0.92 AUC.
Why the study?
The study was conducted to evaluate the external validity of various cardiovascular disease risk assessment tools in predicting CVD events among individuals with metabolic dysfunction-associated steatotic liver disease.
Do cardiovascular risk assessment tools accurately predict future cardiovascular events in individuals with MASLD?
Cohort (n=1,431)
Yes
Do cardiovascular risk assessment tools accurately predict future cardiovascular events in individuals with MASLD?
The ACC/AHA pooled cohort equations demonstrate excellent predictive ability for fatal and composite cardiovascular events in individuals with MASLD, particularly in women, supporting their clinical utility in this population.
Answers are grounded in this paper and cite their sources.
Supports ACC/AHA equations for CVD risk stratification in MASLD; extends validation data but leaves open need for prospective confirmation.
The present study was conducted to evaluate the external validity of various cardiovascular disease (CVD) risk assessment tools in predicting CVD events among individuals with metabolic dysfunction-associated steatotic liver disease (MASLD). The Amol prospective cohort study spanned a follow-up period of seven years, from 2009 to 2010 to 2016-2017. A total of 1,431 individuals aged 40-75 years were included. The 10-year cardiovascular risk was estimated for each participant using four risk assessment tools: the Pooled Cohort Equations of the American College of Cardiology/American Heart Association (ACC/AHA), the Systematic Coronary Risk Evaluation (SCORE) equations, the Framingham General Cardiovascular Risk Profile, and the SCORE2 equations. Receiver Operating Characteristic (ROC) curves were used to assess the discrimination ability of these tools. The ACC/AHA tool demonstrated the highest predictive ability for both fatal CVD events (AUC: 0.92, 95% CI: 0.88-0.97 for men; AUC: 0.87, 95% CI: 0.79-0.96 for women) and composite CVD events (AUC: 0.68, 95% CI: 0.62-0.75 for men; AUC: 0.79, 95% CI: 0.72-0.85 for women). Based on these findings, cardiovascular risk assessment tools, particularly the ACC/AHA tool, can be applied in clinical settings to evaluate the future risk of CVD events in women with MASLD. However, the SCORE equations also exhibited excellent predictive ability for fatal cardiac events, requiring fewer variables.
No takes yet. Share an insight, caveat, or question.
Motamed et al. (2025) conducted a cohort in Metabolic dysfunction-associated steatotic liver disease (MASLD) (n=1,431). ACC/AHA Pooled Cohort Equations vs. SCORE, Framingham, and SCORE2 equations was evaluated on Predictive ability for fatal CVD events in men (AUC 0.92, 95% CI 0.88-0.97). The ACC/AHA cardiovascular risk assessment tool demonstrated the highest predictive ability for fatal CVD events in men and women with MASLD.
Synapse has enriched 10 related papers. Consider them for comparative context: